Our Latest News


New DYNACORD Suture from DePuy Synthes Designed to Help Address Challenges Associated with Rotator Cuff Surgery

JUNE 20, 2018 San Diego, CA – Johnson & Johnson Medical Devices Companies* through the DePuy Synthes** franchise today announces the U.S. launch of DYNACORD Suture to repair soft tissue such as the rotator cuff in the shoulder. Part of the DePuy Synthes Mitek Sports Medicine portfolio, DYNACORD Suture is available on HEALIX ADVANCE Anchors and adds to DePuy Synthes’ innovative solutions designed to help address unmet patient needs in soft tissue repair. DYNACORD Suture was launched today at the San Diego Shoulder Institute’s 35th Annual Course.


DePuy Synthes Launches Innovative Nailing System Aimed at Improving Treatment of Femoral Shaft Fractures in the U.S.

West Chester, PA – June 7, 2018 – DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announces the U.S. launch of its Femoral Recon Nail System, a nailing system that provides new options for the surgical treatment of a wide variety of long thigh bone fractures. This new system builds on the company’s comprehensive trauma portfolio of innovative solutions designed to improve outcomes for patients with hip and femur fractures.


New GLOBAL UNITE Reverse Fracture Shoulder Implant from DePuy Synthes Addresses Unmet Needs in Complex Shoulder Fractures

MAY 22, 2018 Warsaw, IN – DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announces the U.S. launch of the GLOBAL UNITE Reverse Fracture Shoulder, an innovative implant solution for shoulder reconstruction following complex fractures in patients with a grossly deficient rotator cuff. The new system is designed to provide increased flexibility for securely reattaching the bone to the implant, which is important for healing and function, and allowing biological fixation to the stem of the implant with a porous coating to help deliver a consistent surgical outcome. This new offering adds to DePuy Synthes’ commitment to innovative shoulder solutions that address the full continuum of shoulder disorders.


DePuy Synthes Signs Definitive Agreement to Acquire Assets of Medical Enterprises Distribution, LLC to Strengthen its Portfolio and Amplify the Surgeon’s Capabilities Via Automation

Warsaw, Indiana, May 14, 2018 – Consistent with its strategy to transform orthopaedic surgery by building a differentiated and comprehensive digital surgery platform, DePuy Synthes Products, Inc., part of the Johnson & Johnson Medical Devices Companies*, announced today that it has signed a definitive agreement to acquire the assets of Medical Enterprises Distribution, LLC, a privately held developer of surgical impactor technology, including the automated ME1000™ Surgical Impactor for use in hip replacement. The transaction is expected to close in the second quarter of 2018. The closing is subject to antitrust clearance and other customary closing conditions. Financial terms of the acquisition are not being disclosed.


ATTUNE Knee System Linked to Improvements in Patient Quality of Life and Reduced Length of Hospital Stay

Warsaw, Indiana, May 10, 2018: DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announced clinical findings outlining the potential benefits patients may experience when undergoing knee replacement with the ATTUNE Knee System.


DePuy Synthes Announces Agreement with Prosidyan to Exclusively Promote FIBERGRAFT® Family of Products for Spine Fusion Surgery

RAYNHAM, Mass. – May 9, 2018 – DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, today announced an exclusive agreement in the U.S. between DePuy Synthes Sales, Inc. and Prosidyan to promote the FIBERGRAFT® Family of Products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for optimal resorption in clinical use during spine fusion surgery. By adding FIBERGRAFT to its offerings, DePuy Synthes will further enhance the company’s biomaterials portfolio for spine, which currently includes cellular allograft, demineralized bone matrix and first generation synthetic solutions. Surgeons will now have a broad range of handling options based on the needs of each patient and surgical case.